major depressive disorder
Conditions
Interventions
Scopolamine+MECT group:Scopolamine
Placebo+MECT group:Placebo
Sponsors
Chongqing Mental Health Center
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Individuals aged between 18 and 60 years old, irrespective of gender; 2.Individuals able to either read or communicate verbally with sufficient proficiency to sign written informed consent for study participation; 3.Individuals who are eligible for MECT indications, including cases of refractory condition or need for rapid symptom relief; 4. Individuals who meet the diagnostic criteria outlined in the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) for Major Depressive Disorder.
Exclusion criteria
Exclusion criteria: 1.A history of allergy to study medications, specifically hyoscine hydrobromide injection, etomidate emulsion injection, and succinylcholine chloride injection; 2.The presence of contraindications to MECT, or evidence of organic brain disorders including dementia, neurological diseases or injuries, or conditions likely to severely impair neuropsychological function; 3.The absence of pregnancy or risk of pregnancy without adequate contraceptive measures, or breastfeeding; 4.A history of substance abuse or dependence within the past year.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cognitive function;Rate of remission of depressive symptoms;Rate of remission of depressive symptoms; | — |
Secondary
| Measure | Time frame |
|---|---|
| cognitive function;social function;Length of hospital stay;Hospitalisation costs;Hamilton Anxiety Scale score;Time taken for respiratory and consciousness recovery following MECT;Clinical Global Impression Scale score;Vital signs following MECT;Duration of a seizure;adverse reaction;Hamilton Anxiety Scale score;Clinical Global Impression Scale score; | — |
Countries
China
Contacts
Public ContactChen Li
Chongqing Mental Health Center
Outcome results
None listed